drugset / Trial / NCT01926041

The Effectiveness of Smoking Cessation in Prediabetic Smokers

NCT01926041 ↗

Non-randomizedParallel-groupOpen-labelPrevention

Summary

Existing literature investigating the impact of smoking cessation on new-onset diabetes mellitus (DM) risk is conflicting. Combing the need for smoking cessation and body weight self-management to prevent the progression of prediabetes stage into DM, with the public implementation of the second-generation cessation program, we aimed to study the effectiveness of the Fight Tobacco and Stay Fit (FIT2) program aiming at promoting smoking cessation and restricting post-cessation weight gain (PCWG) together in prediabetic smokers regarding long-term glycemic and DM-related health outcomes.

Timeline

Start
2013-08-01
Primary completion
2020-12-31
Completion
2027-12-31

Outcome

Met primary endpoint

registry analysis (superiority test); Intervention (FIT2 Program) vs Usual Care; p = 0.008; Hazard Ratio (HR) 0.64 (95% CI 0.48 to 0.84); NCT01926041 ↗

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Varenicline Small molecule 1 mg —